830346-47-9

Basic information

• Product Name: Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)-
• Synonyms: Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)-;1-(2-Fluoro-6-trifluoromethyl-benzyl)-6-methyl-1H-pyrimidine-2,4-dione;elagolix intermediate 4;1-[2-Fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione;2,4(1H,3H)-Pyrimidinedione, 1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-;4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)-;elagolix intermediate
• CAS NO: 830346-47-9
• Molecular Formula: C₁₃H₁₀F₄N₂O₂
• Molecular Weight: 302.2243128
• Mol File: 830346-47-9.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• Density: 1.413g/cm³
• Refractive Index: 1.511
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.49±0.40(Predicted)
• CAS DataBase Reference: Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)-(830346-47-9)
• EPA Substance Registry System: Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)-(830346-47-9)

Safety Data

• Hazardous Substances Data: 830346-47-9(Hazardous Substances Data)

Usage

General Description

Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)- is a chemical compound with the molecular formula C11H13FO2. It is also known as levofenac and is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain and reduce inflammation. It works by inhibiting the production of prostaglandins, which are substances in the body that cause pain and inflammation. Levofenac is commonly prescribed for conditions such as osteoarthritis, rheumatoid arthritis, and acute pain. It is available in various forms, including tablets, injections, and topical gels, and is typically well-tolerated by most patients, although like all NSAIDs, it can cause side effects such as stomach upset and gastrointestinal bleeding.

InChI:InChI=1/C13H10F4N2O2/c1-7-5-11(20)18-12(21)19(7)6-8-9(13(15,16)17)3-2-4-10(8)14/h2-5H,6H2,1H3,(H,18,20,21)

Upstream product

• 830346-46-8 N-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}urea 
• 72324-39-1 5-acetyl-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 626-48-2 6-Methyluracil 
• 239087-08-2 2-(bromomethyl)-1-fluoro-3-(trifluoromethyl)benzene 
• 5394-63-8 2,2,6-trimethyl-4H-1,3-dioxin-4-one 
• 133116-83-3 2-fluoro-6-(trifluoromethyl)benzonitrile 
• 1694-31-1 tert-butyl acetoacetate 
• 463-51-4 Ketene 
• 75-77-4 chloro-trimethyl-silane 
• 674-82-8 4-methyleneoxetan-2-one 
• 2911-21-9 2,4-dioxo-6-methyl-3,4-dihydro-2H-1,3-oxazine 
• 239087-06-0 (2-fluoro-6-(trifluoromethyl) phenyl)methanamine 
• 31111-31-6 6-methyl-2,4-bis(trimethylsiloxy)pyrimidine 
• 152211-15-9 (2-fluoro-6-(trifluoromethyl)phenyl)methanol 

Downstream Products

• 830346-48-0 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4-(1H,3H)-dione 
• 1150560-54-5 1-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-5-iodo-6-methylpyrimidine-2,4(1H,3H)-dione 
• 1150560-59-0 5-(2-fluoro-3-methoxyphenyl)-1-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-6-methylpyrimidine-2,4(1H,3H)-dione 
• 830346-50-4 3-[(2R)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-2,4(1H,3H)-pyrimidinedione trifluoroacetate 
• 832720-84-0 4-((R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-trifluoromethylbenzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidine-1-yl]-1-phenylethylamino)butyric acid ethyl ester 
• 830346-51-5 (R)-(2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)carbamic acid tert-butyl ester 
• 830346-49-1 {(R)-2-[5-bromo-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 869984-36-1 C₄₂H₄₉F₄N₃O₇ 
• 869984-33-8 C₃₇H₃₉F₄N₃O₇ 

Relevant articles and documents

Preparation method of olagolide intermediate

The present invention relates to a method for preparing a lacolagoli intermediate 5-bromo-1- {[2-fluoro-6-(trifluoromethyl)phenyl] methyl}-6-methyl-2,4 (1H, 3H) pyrimidinedione (compound of formula I), in particular, a compound of formula III with 2-fluor

AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention relates to an improved process for the preparation of 4- ({(1R) -2- [5- (2-fluoro- 3- methoxy phenyl) – 3 - {[ 2-fluoro- 6-(trifluoro methyl) phenyl] methyl} -4-methyl- 2,6-dioxo- 3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino) butanoic acid of formula (I) or its pharmaceutically acceptable salts. The compound of formula (I) is represented by the following structural formula.

Preparation method of compound containing 6-methyluracil structure

The invention discloses a preparation method of a compound containing a 6-methyluracil structure. The invention relates to the technical field of synthesis of medical intermediates and organic chemical intermediates. The method comprises the following synthesis steps of: (1) reacting ethyl carbamate serving as a compound 1 with ethyl acetoacetate serving as a compound 2 under a heating condition under the action of an organic solvent and a catalyst to generate a compound 3 that is oxazine diketone; and (2) reacting the compound 3 with a compound 4 that is 2-fluoro-6-(trifluoromethyl) phenyl) methylamine under the condition of heating, an organic solvent or no solvent to generate a compound 5, i.e., a 6-methyl-uracil substituted derivative. The method disclosed by the invention is suitablefor industrial production and relatively low in cost, and the prepared product is high in purity and yield.